Generated by AI
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s commercial portfolio centers on vonoprazan-based therapies, including VOQUEZNA for the relief of heartburn associated with non-erosive and erosive GERD and the healing and maintenance of erosive GERD in adults. It also markets VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK for the treatment of Helicobacter pylori infection in adults. Phathom Pharmaceuticals operates as a specialist in acid-related GI disorders, combining research, product development, and commercialization to address conditions that affect the digestive system.
Website100 Campus Drive
Florham Park, NJ, 07932
United States
The latest articles about PHAT.
Phathom Pharmaceuticals has spent 2026 in the spotlight for very different reasons. On one side, Q3 results showed higher revenue and a smaller loss, and management reaffirmed a target for operating profitability in 2026. For Phathom Pharmaceuticals shareholders, the loss from the start of the year was 63.5%, including dividends. If you were weighing a fresh position after that drop, would the improving cost profile and new VOQUEZNA data justify taking that risk? This theme extends beyond...
Summary of Nov 11's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Investors talking about PHAT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.